Available company data, source links and archived checks for Regeneron Pharmaceuticals. Read each source and date: a past check is not a fresh review, and some earlier figures have incomplete source details.
Quarter ended 2026-06-30 · consolidated · Company filing
| Quarter | Revenue / income | YoY | Profit | YoY | Net margin | Source |
|---|---|---|---|---|---|---|
| Jun 2026 | Revenue: $4.3 bn | +16.7% | Net profit: $1.3 bn | -6.8% | 30.2% | Company filing source |
| Mar 2026 | Revenue: $3.6 bn | +19.0% | Net profit: $727 mn | -10.1% | 20.2% | Company filing source |
| Dec 2025 | Revenue: $3.9 bn | +2.5% | Net profit: $845 mn | -8.0% | 21.7% | Company filing source |
| Sep 2025 | Revenue: $3.8 bn | +0.9% | Net profit: $1.5 bn | +8.9% | 38.9% | Company filing source |
| Jun 2025 | Revenue: $3.7 bn | +3.6% | Net profit: $1.4 bn | -2.8% | 37.9% | Company filing source |
| Mar 2025 | Revenue: $3.0 bn | -3.7% | Net profit: $809 mn | +12.0% | 26.7% | Company filing source |
YoY means change from the same quarter a year earlier. — means no comparable figure is available. Older entries with incomplete source details have not been revalidated under the current checks.
(In millions)
Column boundaries are incomplete. Use the source document to interpret these figures.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Class A Stock | | Common Stock | | Additional Paid-in Capital | | Retained Earnings | | Accumulated Other Comprehensive Income (Loss) | | Treasury Stock | | Total Stockholders' Equity | | | Shares | | Amount | | Shares | | Amount | | | | | Shares | | Amount | |
Balance, December 31, 2025
Column boundaries are incomplete. Use the source document to interpret these figures.
| | 1.8 | | $ | — | | | 137.6 | | $ | 0.1 | | | $ | 13,995.0 | | | $ | 35,797.1 | | | $ | 77.5 | | | (33.7) | | $ | (18,612.8) | | | $ | 31,256.9 | | Issuance of Common Stock for equity awards granted under long-term incentive plans | | — | | | — | | | 0.3 | | | — | | | 167.0 | | | — | | | — | | | — | | | — | | | 167.0 | | Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations | | — | | | — | | | — | | | — | | | (29.1) | | | — | | | — | | | — | | | — | | | (29.1) | | Issuance/distribution of Common Stock for 401(k) Savings Plan | | — | | | — | | | — | | | — | | | 21.5 | | | — | | | — | | | — | | | 2.5 | | | 24.0 | | Repurchases of Common Stock | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (1.0) | | | (803.2) | | | (803.2) | |
Dividends declared
Column boundaries are incomplete. Use the source document to interpret these figures.
| | — | | | — | | | — | | | — | | | — | | | (100.5) | | | — | | | — | | | — | | | (100.5) | | Stock-based compensation charges | | — | | | — | | | — | | | — | | | 246.9 | | | — | | | — | | | — | | | — | | | 246.9 | | Net income | | — | | | — | | | — | | | — | | | — | | | 727.2 | | | — | | | — | | | — | | | 727.2 | |
Other comprehensive loss, net of tax
Column boundaries are incomplete. Use the source document to interpret these figures.
| | — | | | — | | | — | | | — | | | — | | | — | | | (65.6) | | | — | | | — | | | (65.6) | |
Balance, March 31, 2026
A valuation allowance is established where it is more likely than not some or all deferred tax assets will not be realized.
Acquired IPR&D expenses for the three and six months ended June 30, 2026 included up-front and opt-in payments under collaboration and licensing agreements; the six-month period also included the premium on purchased equity securities and development milestone payments.
An unsuccessful, delayed or difficult implementation of the new ERP system could prevent realization of anticipated productivity improvements or cost efficiencies and cause operational difficulties.
As of December 31, 2025, we had $3.118 billion in cash and cash equivalents and $16.229 billion in marketable and other securities (including $515.8 million in equity securities). Our investments consist primarily of debt securities, including investment-grade corporate bonds. These fixed-income investments are subject to external factors that may adversely affect their market value or liquidity, such as interest rate, liquidity, market, and issuer credit risks, including actual or anticipated changes in credit ratings. The equity securities we hold may experience significant volatility and may decline in value or become worthless if the issuer experiences an adverse development. Furthermore, our equity investments could be subject to dilution (and decline in value) as a result of the issuance of additional equity interests by the applicable issuer. If any of our investments suffer market price declines, such declines may have an adverse effect on our financial condition and operating results.
Keep its available filings, dated fact checks and disclosure alerts together. Your saved country sets your market and its research schedule.
Start free — first week on us →Company data and archived claim checks are shown with available sources. Check the source and date before relying on a figure. This is not investment advice or a recommendation. Investment in securities markets is subject to market risks. Research on this site is produced with substantial use of AI. Terms, disclosures and grievances